Success Metrics

Completion Rate
0%(0/2)
Active Trials
0(0%)
Terminated
2(67%)

Phase Distribution

Ph phase_2
3
100%

Phase Distribution

0

Early Stage

3

Mid Stage

0

Late Stage

Phase Distribution3 total trials
Phase 2Efficacy & side effects
3(100.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

0.0%

0 of 3 finished

Non-Completion Rate

100.0%

3 ended early

Currently Active

0

trials recruiting

Total Trials

3

all time

Status Distribution
Terminated(3)

Detailed Status

Terminated2
Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials
3
Active
0
Success Rate
0.0%
Most Advanced
Phase 2

Trials by Phase

Phase 23 (100.0%)

Trials by Status

withdrawn133%
terminated267%

Recent Activity

0 active trials
Showing 3 of 3
terminatedphase_2

RaPiDS- A Phase 2 Study of Anti-PD-1 Independently or in Combination With Anti-CTLA-4 in Second-Line Cervical Cancer

NCT03894215
terminatedphase_2

AGEN1884 Plus AGEN2034 Combined With Cisplatin-Gemcitabine for Muscle-Invasive Bladder Cancer

NCT04430036
withdrawnphase_2

AGEN2034 & AGEN1884 in Patients With Recurrent, Inoperable Angiosarcoma

NCT04607200

Clinical Trials (3)

Showing 3 of 3 trials
NCT03894215Phase 2

RaPiDS- A Phase 2 Study of Anti-PD-1 Independently or in Combination With Anti-CTLA-4 in Second-Line Cervical Cancer

Terminated
NCT04430036Phase 2

AGEN1884 Plus AGEN2034 Combined With Cisplatin-Gemcitabine for Muscle-Invasive Bladder Cancer

Terminated
NCT04607200Phase 2

AGEN2034 & AGEN1884 in Patients With Recurrent, Inoperable Angiosarcoma

Withdrawn

All 3 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
3